• PDF: Delivered by email usually within 48 UK business hours.

Hanmi Pharmaceutical Co Ltd (008930) - Pharmaceuticals & Healthcare
Deals and Alliances Profile

  • Publication Date:March 2011
  • Publisher:GlobalData
  • Product Type: Report
  • Pages:54

Hanmi Pharmaceutical Co Ltd (008930) - Pharmaceuticals & Healthcare Deals and Alliances Profile

Hanmi Pharmaceutical Co Ltd (008930) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Hanmi Pharmaceutical Co., Ltd. (Hanmi ) is a Korea based manufacturer and supplier of pharmaceuticals. It is engaged in providing over-the-counter (OTC) drugs, prescription drugs and active pharmaceutical ingredients (APIs). The company's OTC products comprises of expectorants, cough remedies, remedies for gastrointestinal diseases and inflammations, and others such as eye drops, vitamins and nutrition. Hanmi's prescription drugs include ophthalmic agents, antifungal agents, anticancer agents, antibiotics and remedies for skin diseases, among others. Its APIs include cefotaxime, ceftriaxone, ceftazidime and cefixime. The company is also involved in the research and development of new drugs, biopharmaceuticals and anticancer agents through its research center. Hanmi also exports its medicines to overseas countries. The company is headquartered in Seoul, Korea.

Hanmi Pharmaceutical Co Ltd (008930) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you an in-depth data and trend analysis of the company's mergers and acquisitions (M&A) and financings. The report provides detailed information on M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions registered by the company over a five year period. The report portrays detailed comparative data on the number of deals and their value subdivided by deal types, markets, and regions, besides highlighting the company's major recent financial deals.

Data presented in this report was derived from GlobalData's proprietary in-house Pharmaceuticals and Healthcare eTrack deals database and primary and secondary research.

Scope

  • Financial Deals - Analysis of the company's financial deals including M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information on the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information on the number of deals and value reported by the company by type such as M&A, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region for North America, Europe, the Middle East and Africa and South and Central America.
  • Deals by Market - Chart and table showing information on the number of deals and value reported by the company, by market.
  • Major Recent Deals - Information on the company's major recent financial deals. Each such deal has a brief summary, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key Competitors - A list of key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements.

  • The profile analyzes the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divesture strategy

  • Deals are presented from the company's core business segments' perspective to help you understand its corporate strategy

Access detailed information about the company's recent financial deals that enables you to understand the key deals which have shaped the company

  • Major recent deals are presented in detail, which provides information on each deal's brief summary, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company to identify potential customers and suppliers.

  • The profile analyzes the company's business structure, locations and subsidiaries, key executives and their biographies and key competitors.

Stay up to date on the major developments affecting the company

  • Recent developments in the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research.

  • Key elements such as break up of deals by categories and information on detailed major deals are incorporated in the profile to assist your academic or business research needs.
  • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Medical Devices Deals, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details
    • Asset Purchase
    • Hanmi Pharmaceutical Acquires Patent For Mass Production Of Immunoglobulin
    • Hanmi Pharmaceutical Acquires Patent Of Protein Complex
    • Hanmi Pharmaceutical Acquires Patent For Making Method Of Cefdinir
    • Hanmi Pharmaceutical Acquires Patent Of Azithromycin And Crystalline
    • Hanmi Pharmaceutical Acquires Patent Of Clathrate
    • Hanmi Pharmaceutical Acquires Patent For Preparing Amorphous Taclolimus Solid Dispersion
    • Hanmi Pharmaceutical Acquires Patent For Syrup Composition
    • Hanmi Pharmaceutical Acquires Patent For Preparing Clopidogrel
    • Hanmi Pharmaceutical Acquires Patent Of Carboxylic
    • Hanmi Acquires US Patent Of 3-(Z)-Propenyl Cephem
    • Partnerships
    • Hanmi Pharmaceutical Enters Into Co-Marketing Agreement With Baxter
    • H. Lundbeck Enters Into Co-Marketing Agreement With Hanmi Pharmaceutical
    • Hanmi Pharmaceutical Enters Into Co-Marketing Agreement With GlaxoSmithKline
    • LegoChem Biosciences Enters Into Research Agreement With Hanmi Pharmaceutical
    • CrystalGenomics Partners With Hanmi Pharmaceutical
    • Hanmi Pharmaceutical Enters Into Research Collaboration Agreement With Antitope
    • Hanmi Pharmaceutical Enters Into Strategic Partnership With CrystalGenomics
    • Licensing Agreements
    • Hanmi Pharmaceutical Enters Into Licensing Agreement With Hwail Pharma For Entecavir
    • Hanmi Pharmaceutical Enters Into Licensing Agreement With Whail Pharmaceuticals
    • Equity Offering
    • Hanmi Pharmaceutical Completes Public Offering Of $1 Million
    • Acquisition
    • Hanmi Pharmaceutical Acquires 12.8% Stake In CrystalGenomics
    • Hanmi Pharmaceutical Acquires 9.13% Stake In Dong-A Pharmaceutical
    • Hanmi Pharmaceutical Acquires Japan-Based Company
    • Hanmi Pharmaceutical Acquires 6.27% Stake In Dong-A Pharmaceutical
    • Hanmi Pharmaceutical Acquires 9% Stake In Hanmi IT
    • Key Competitors
    • Key Employees
    • Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
    • Recent Developments
    • Financial Announcements
    • Nov 15, 2006: Hanmi, 3rd Quater Management Performance
    • Apr 21, 2006: Provisional 2nd Quarter Result
    • Feb 17, 2004: Jans Etc Sales Up By 31%
    • Feb 04, 2004: Hanmi, Expected 19% Of Sales Growth In 2004
    • Corporate Communications
    • Jan 03, 2011: Hanmi Pharmaceuticals Announces Management Changes
    • Dec 30, 2009: Hanmi Pharmaceuticals Announces New Appointments
    • Product News
    • Dec 09, 2008: New Regulation In Effect: Imd To Fetch 90% Of Original Drug Prices
    • Dec 02, 2008: Hanmi To Enter A 100 Billion Won Market With Polybone
    • Nov 23, 2009: Hanmi Pharmaceuticals, 1st Place In R&D Investment Among Korean Pharmas
    • Nov 21, 2005: In Contact With Patent Holding Roche, Mass Production Is Possible Immediately After The License Release
    • Oct 14, 2009: Hanmis Laps-Gcsf Got The Us Fdas Approval For Clinical Trials
    • Oct 04, 2005: 36 Billion Won Of Sales For One Year Since Its Launch
    • Sep 21, 2009: Hanmi's 'laps-Epo' Got An Ind Approval From Us Fda
    • Sep 04, 2009: Wrangle Between Ministry For Health, Welfare, And Family Affair-The Medical Profession And The Pharmaceuticals Looms Larger
    • Aug 28, 2009: Hanmi Targets Overseas Market Using Sales Force Of Merck
    • Aug 19, 2009: Several Brand-Name Drugs Suffered From Price Cuts
    • Aug 18, 2009: Hanmi Targets Us Market With Esomezole
    • Jul 31, 2009: Hanmi Targets Australian / European Market With Slimmer/Pidogul
    • Jul 31, 2009: Hanmi's "amosartan" Leads Hypertension Combination Drug Market In Korea
    • Jul 21, 2009: Hanmi Targets Overseas Market Using Sales Force Of Merck
    • Jun 09, 2008: Hanmi To Roll Out Its Generic Lipitor Next Year
    • May 19, 2010: Phase 1 Underway For Atorvastatin Plus Aspirin Fixed Dose Combination Drug
    • May 14, 2008: Hanmi's Super Generic To U.S. Market
    • Apr 27, 2010: Hanmi Submits Impd In Europe For Phase I Clinical Trials Of Laps-Exendin
    • Apr 24, 2009: Korean Drugmakers Beat Multinational Ones
    • Mar 04, 2010: Hanmi Wins The Best Drug Research Award Of Kdra
    • Feb 13, 2009: Government Aiding New Drugs Development By Funding Half The Costs
    • Feb 11, 2008: Hanmi Fine Chemical., One Of The Hanmi Pharmaceutical Company's Affiliates, Got An Approval From Us Fda For The Third Generation Injection Type Antibiotics
    • Feb 01, 2010: Ind Application For Long-Acting Human Growth Hormone Approved
    • Jan 12, 2010: Kfda Approves Ind Application Of Once Monthly Exendin4 Analog
  • Appendix
    • Methodology
    • About GlobalData
    • Contact Us
    • Disclaimer 54
  • List of Tables
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2008
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Deals By Therapy Area, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Medical Devices Deals, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Phase Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2005 to YTD 2011
    • Hanmi Pharmaceutical Acquires Patent For Mass Production Of Immunoglobulin
    • Hanmi Pharmaceutical Acquires Patent Of Protein Complex
    • Hanmi Pharmaceutical Acquires Patent For Making Method Of Cefdinir
    • Hanmi Pharmaceutical Acquires Patent Of Azithromycin And Crystalline
    • Hanmi Pharmaceutical Acquires Patent Of Clathrate
    • Hanmi Pharmaceutical Acquires Patent For Preparing Amorphous Taclolimus Solid Dispersion
    • Hanmi Pharmaceutical Acquires Patent For Syrup Composition
    • Hanmi Pharmaceutical Acquires Patent For Preparing Clopidogrel
    • Hanmi Pharmaceutical Acquires Patent Of Carboxylic
    • Hanmi Acquires US Patent Of 3-(Z)-Propenyl Cephem
    • Hanmi Pharmaceutical Enters Into Co-Marketing Agreement With Baxter
    • H. Lundbeck Enters Into Co-Marketing Agreement With Hanmi Pharmaceutical
    • Hanmi Pharmaceutical Enters Into Co-Marketing Agreement With GlaxoSmithKline
    • LegoChem Biosciences Enters Into Research Agreement With Hanmi Pharmaceutical
    • CrystalGenomics Partners With Hanmi Pharmaceutical
    • Hanmi Pharmaceutical Enters Into Research Collaboration Agreement With Antitope
    • Hanmi Pharmaceutical Enters Into Strategic Partnership With CrystalGenomics
    • Hanmi Pharmaceutical Enters Into Licensing Agreement With Hwail Pharma For Entecavir
    • Hanmi Pharmaceutical Enters Into Licensing Agreement With Whail Pharmaceuticals
    • Hanmi Pharmaceutical Completes Public Offering Of $1 Million
    • Hanmi Pharmaceutical Acquires 12.8% Stake In CrystalGenomics
    • Hanmi Pharmaceutical Acquires 9.13% Stake In Dong-A Pharmaceutical
    • Hanmi Pharmaceutical Acquires Japan-Based Company
    • Hanmi Pharmaceutical Acquires 6.27% Stake In Dong-A Pharmaceutical
    • Hanmi Pharmaceutical Acquires 9% Stake In Hanmi IT
    • Hanmi Pharmaceutical Co Ltd, Key Employees
    • Hanmi Pharmaceutical Co Ltd, Subsidiaries 43
  • List of Figures
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Licensing Deals by Year, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Licensing Deals by Phase, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011
    • Hanmi Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Medical Devices Deals, 2005 to YTD 2011
+44 20 8816 8548

Ask a question about Hanmi Pharmaceutical Co Ltd (008930) - Pharmaceuticals & Healthcare

Enter the characters you see in the picture below
Captcha